华熙生物(688363) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥1,145,823,331.38, a decrease of 17.26% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥89,792,177.94, down 56.03% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥72,361,244.04, a decline of 61.53% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.19, a decrease of 55.81% year-on-year[5]. - The diluted earnings per share for Q3 2023 was also ¥0.19, reflecting a 55.81% decline compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2023 was approximately ¥4.22 billion, a decrease of 2.3% compared to ¥4.32 billion in the same period of 2022[21]. - Net profit for the third quarter of 2023 was approximately ¥507.08 million, down 24% from ¥667.16 million in the same quarter of 2022[25]. - Earnings per share for the third quarter of 2023 were ¥1.07, compared to ¥1.41 in the same quarter of 2022, reflecting a decrease of 24%[26]. - The total comprehensive income for the third quarter of 2023 was approximately ¥514.87 million, down from ¥658.76 million in the same quarter of 2022, a decrease of 21.8%[26]. Research and Development - The total R&D investment for the period was ¥90,408,566.44, a decrease of 7.56% year-on-year, with R&D expenses accounting for 7.89% of operating revenue, an increase of 0.83 percentage points[5]. - Research and development expenses remained stable at approximately ¥277 million for both years, indicating a consistent investment in innovation[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,349,563,535.99, a decrease of 3.83% compared to the end of the previous year[5]. - Current assets totaled RMB 3,207,373,119.40, down from RMB 4,023,100,101.48 in the previous year, reflecting a decline of about 20.2%[18]. - The company's cash and cash equivalents decreased from RMB 1,606,128,994.81 in December 2022 to RMB 1,127,091,845.15, a reduction of approximately 29.7%[18]. - The total liabilities decreased from approximately ¥1.99 billion in the previous year to ¥1.38 billion in the current year, a reduction of about 30.8%[22]. - The total equity attributable to shareholders increased to approximately ¥6.93 billion in 2023 from ¥6.63 billion in 2022, an increase of 4.4%[24]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥234,889,218.06, reflecting a significant increase of 101.64%[5]. - In the first three quarters of 2023, the cash inflow from operating activities was approximately CNY 4.68 billion, a decrease of 2.84% compared to CNY 4.82 billion in the same period of 2022[27]. - The net cash outflow from operating activities in the first three quarters of 2023 was CNY 234.89 million, an increase of 101.9% compared to CNY 116.49 million in the same period of 2022[28]. - The cash outflow from investing activities in the first three quarters of 2023 was CNY 1.85 billion, a decrease of 44.4% compared to CNY 3.33 billion in the same period of 2022[28]. - The total cash and cash equivalents at the end of Q3 2023 was CNY 692.96 million, down from CNY 748.01 million at the end of Q3 2022[29]. Share Repurchase - The company has repurchased a total of 95,456 shares, accounting for 0.0198% of the total share capital, with a total expenditure of RMB 8,388,185.94[16]. - The highest repurchase price was RMB 89.71 per share, while the lowest was RMB 86.41 per share[16]. - The company plans to use between RMB 200 million and RMB 300 million for share repurchase, with a maximum price of RMB 130.00 per share[16]. Other Financial Metrics - The weighted average return on equity for Q3 2023 was 1.35%, down 1.95 percentage points from the previous year[5]. - The company reported a decrease in tax expenses from approximately ¥152.23 million in 2022 to ¥103.34 million in 2023, a reduction of 32%[24]. - Other comprehensive income attributable to shareholders was approximately ¥7.79 million in 2023, compared to a loss of ¥8.40 million in 2022[25]. - The company experienced a negative impact of CNY 7.20 million from exchange rate fluctuations on cash and cash equivalents in Q3 2023[29]. - The company did not apply the new accounting standards starting in 2023, indicating a continuation of previous accounting practices[29].